https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-31 / Sci Rep 2018 Jul;8(1):11470
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-31 / Sci Rep 2018 Jul;8(1):114702018-07-31 00:00:002019-02-15 09:00:24Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-30 / Oncoimmunology 2018;7(12):e1474318
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-30 / Oncoimmunology 2018;7(12):e14743182018-07-30 00:00:002018-07-30 00:00:00Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-30 / Clin. Exp. Med. 2018 Nov;18(4):535-546
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-30 / Clin. Exp. Med. 2018 Nov;18(4):535-5462018-07-30 00:00:002018-07-30 00:00:00Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-27 / Cancer Immunol. Immunother. 2018 Oct;67(10):1545-1558
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-27 / Cancer Immunol. Immunother. 2018 Oct;67(10):1545-15582018-07-27 00:00:002019-02-15 08:47:42High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T depletion
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-26 / Ther Clin Risk Manag 2018;14:1299-1313
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-26 / Ther Clin Risk Manag 2018;14:1299-13132018-07-26 00:00:002019-02-15 08:47:37Dendritic cell vaccines for high-grade gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
root
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
root2018-07-24 18:56:262020-05-27 11:18:50IOZK-Artikel über Heilversuche bei Glioblastom im Fachorgan: „Austin Oncology Case Report“
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-23 / 2018;7(9):e1476817
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-23 / 2018;7(9):e14768172018-07-23 00:00:002018-07-23 00:00:00Vitamin D deficiency in head and neck cancer patients – prevalence, prognostic value and impact on immune function
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-23 / Cancer Immunol. Immunother. 2018 Oct;67(10):1505-1518
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-23 / Cancer Immunol. Immunother. 2018 Oct;67(10):1505-15182018-07-23 00:00:002019-02-15 08:32:52A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-18 / BMC Cancer 2018 Jul;18(1):746
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-18 / BMC Cancer 2018 Jul;18(1):7462018-07-18 00:00:002018-07-18 00:00:00Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-12 / 2018 Jul;7(7)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-12 / 2018 Jul;7(7)2018-07-12 00:00:002018-07-12 00:00:00Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials
